Drugs / CDX-527
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04440943 | Aug 2020 → Apr 2023 | breast cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer +8 | Celldex Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-04 | Celldex Therapeutics | Results Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting celldex.com ↗
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-04 | Celldex Therapeutics | Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting celldex.com ↗ |
| 2020-08-24 | Celldex Therapeutics | Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors celldex.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04440943 ↗ |
| Route | Other | “administered by infusion” NCT04440943 ↗ |